LONDON Tue May 27, 2014 7:01pm EDT
<span id="articleText"/> LONDON May 28 (Reuters) - Britain's healthcare cost-effectiveness watchdog is recommending Sanofi's new multiple sclerosis drug Lemtrada as a treatment option on the state health service, it said on Wednesday.
<span id="midArticle_0"/> The green light follows previous uncertainty about the value of the product, which led the National Institute for Health and Care Excellence (NICE) to call in December for more information from the manufacturer.
<span id="midArticle_1"/> Lemtrada, an injectable treatment also known as alemtuzumab, was approved in Europe in September. It is still awaiting approval in the United States, where experts have raised questions about its safety and the quality of clinical studies.
<span id="midArticle_2"/> The drug was at the heart of Sanofi's $20.1 billion takeover battle for U.S. biotech firm Genzyme, which developed the drug for relapsing-remitting multiple sclerosis. The medicine was originally invented by scientists at the University of Cambridge, who started work on it in 1991.
<span id="midArticle_3"/> As part of the takeover deal, Genzyme shareholders received contingent value rights, known as CVRs, entitling them to future payments of up to $14 a share, depending on the success of Lemtrada. (Reporting by Ben Hirschler; Editing by David Goodman)
<span id="midArticle_4"/>
<span id="articleText"/> LONDON May 28 (Reuters) - Britain's healthcare cost-effectiveness watchdog is recommending Sanofi's new multiple sclerosis drug Lemtrada as a treatment option on the state health service, it said on Wednesday.
<span id="midArticle_0"/> The green light follows previous uncertainty about the value of the product, which led the National Institute for Health and Care Excellence (NICE) to call in December for more information from the manufacturer.
<span id="midArticle_1"/> Lemtrada, an injectable treatment also known as alemtuzumab, was approved in Europe in September. It is still awaiting approval in the United States, where experts have raised questions about its safety and the quality of clinical studies.
<span id="midArticle_2"/> The drug was at the heart of Sanofi's $20.1 billion takeover battle for U.S. biotech firm Genzyme, which developed the drug for relapsing-remitting multiple sclerosis. The medicine was originally invented by scientists at the University of Cambridge, who started work on it in 1991.
<span id="midArticle_3"/> As part of the takeover deal, Genzyme shareholders received contingent value rights, known as CVRs, entitling them to future payments of up to $14 a share, depending on the success of Lemtrada. (Reporting by Ben Hirschler; Editing by David Goodman)
<span id="midArticle_4"/>
- Link this
- Share this
- Digg this
- Reprints
via Smart Health Shop Forum http://ift.tt/1phbPjA
No comments:
Post a Comment